checkAd
    Legend Biotech Corporation Aktie
    44,42
     
    USD
    -1,66 %
    -0,75 USD
    Letzter Kurs 02:00:00 Nasdaq
    44,41
     
    USD
    2.100 STK
    Geldkurs 25.04.24
    44,43
     
    USD
    400 STK
    Briefkurs 25.04.24
    ISIN: US52490G1022 · WKN: A2P5AH · SYM: LEGN · Kaiman-Inseln

    Neueste Nachrichten

    CARVYKTI (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    22.04.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
    11.04.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech’s CARVYKTI (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
    06.04.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
    19.03.24 · Business Wire (engl.) · Legend Biotech Corporation
    CARVYKTI (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
    15.03.24 · Business Wire (engl.) · Legend Biotech Corporation
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 11.03.2024
    11.03.24 · wO Chartvergleich · DMG MORI
    Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
    11.03.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech Announces Positive CHMP Opinion for CARVYKTI (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
    23.02.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
    13.02.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
    03.01.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
    02.01.24 · Business Wire (engl.) · Legend Biotech Corporation
    Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI (ciltacabtagene autoleucel)
    12.12.23 · Business Wire (engl.) · Legend Biotech Corporation